No Data
No Data
A visual guide to understanding the 2024 interim report of Hualing Pharmaceuticals-B (02552.HK)
On August 29, Hualing Pharmaceuticals-B(02552.HK) released its 2024 interim report. The following infographic will help you understand it.
Express News | Hua Medicine H1 Pretax Profit RMB -142.2 Million
Express News | Hua Medicine H1 Revenue RMB 102.7 Million
HUA MEDICINE-B: INTERIM RESULTS ANNOUNCEMENT FORTHE SIX MONTHS ENDED JUNE 30, 2024
Hualing Pharmaceuticals-B (02552.HK) held a board of directors meeting on August 29 to consider and approve the mid-term performance.
China State-Owned Enterprise Hualing Pharmaceutical (02552.HK) announced that the board of directors meeting will be held on Thursday, August 29, 2024 to consider and approve the interim performance of the group ending on June 30, 2024, and related announcements, as well as to deal with other matters.
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
No Data